Spanish drugmaker Grifols SA paid a higher price to buy blood plasma from an entity linked to its controlling family than ...

Spanish plasma-derived medicines specialist Grifols (MCE: GRF) announced that the positive Phase III study data on its fibrinogen concentrate, BT524, has been published in eClinicalMedicine, a ...

XL-protein GmbH, a pioneer in the area of biopolymers for pharmacokinetic optimization, announced today that it has entered into a worldwide License, Development and Commercialization Agreement with ...

The global acute on chronic liver failure (ACLF) market is witnessing a transformation with a focus on innovative solutions like gene therapies and r ...

U.S. court lets Grifols sue Gotham City for defamation over short report, but dismisses most claims in major financial free speech case.

Detailed price information for Grifols S.A. ADR (GRFS-Q) from The Globe and Mail including charting and trades.

Shares of Grifols have increased 8.89% over the past quarter, and have gained 15.12% in the last year. In comparison, the S&P 500 has only moved 3.59% and 14.21%, respectively.

Dreieich, 23 June 2025. Biotest today announces that the positive Phase III study data on its fibrinogen concentrate, BT524, has been published in eClinicalMedicine, a peer-reviewed journal published ...

Privately-owned German biotech XL-protein GmbH today announced that it has entered into a worldwide license, development and commercialization agreement with Spanish plasma-derived medicines ...

Plasma, by the way, is the liquid part of blood and is a vital input into our health-care system. While some is used directly ...

Below, we take a look at Grifols (GRFS), which currently has a Momentum Style Score of A. We also discuss some of the main drivers of the Momentum Style Score, like price change and earnings ...

We award CSL a narrow moat rating based on the cost advantage afforded by its large-scale plasma collection and fractionation, and intangible assets based on the intellectual capital in its existing ...